Céline Sarr, Ph.D.

Principal Director, MIDD Consultant

Portrait-of-Celine-Sarr_Pharmetheus

Bio

  • Joined Pharmetheus in 2016, actively working in client projects, leading the Client Operations Forum, and serving as Project Portfolio Team Leader and Pharmacometrics Platform Business Development Lead
  • Expertise includes pharmacometrics, submission, pediatric investigation plans, and MIDD support in therapeutic areas such as oncology and metabolism disorders
  • Previously worked as Senior Consultant at SGS-Exprimo, Belgium, where she delivered modeling results to support submissions and internal decisions, as Senior Expert Modeler at Novartis, Switzerland, Cluster Leader at Novartis, USA, and Modeler at Novartis, Switzerland
  • Pharm.D. (2004) from University Paris XII, France, and Ph.D. in Pharmaceutical Biosciences (2006) from University Lyon Claude Bernard, France
LinkedInGoogle Scholar

Pharmetheus affiliated publications

Risks encountered when not adjusting for diurnal variation and food effect in QTcF analysis based on Phase I dataDose Modifications in Exposure-Response Analyses of Oncology Drug Development: Brigimadlin Case StudyApplication of model-informed drug development for dose optimization of brigimadlin in patients with dedifferentiated liposarcomaExposure‐tumour growth inhibition modelling of brigimadlin using phase I solid tumour data to support phase II dose selectionIntegrated modeling of biomarkers, survival and safety in clinical oncology drug developmentPharmacokinetic-pharmacodynamic analysis of drug liking blockade by buprenorphine subcutaneous depot (CAM2038) in participants with opioid use disorderA framework for prediction of progression free survival based on modelling of sub-endpointsApplication of tumor size modelling and simulations to support the dose selection of BI 907828 for a Phase II studyPopulation PK analysis of Pegaspargase in Japanese and non-Japanese patients with acute lymphoblastic leukemiaHow to Successfully Generate an Alternative Approach to a Thorough QT Study: GLPG1972 as an ExampleExposure–Safety Analyses of Nintedanib in Patients with Chronic Fibrosing Interstitial Lung Disease